Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C
Authors:
Open Access
- 1 January 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (1) , 78-84
Abstract
Background. Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging asKeywords
This publication has 14 references indexed in Scilit:
- Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2007
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2005
- Treatment With Pegylated Interferon and Ribavarin in Hcv Infection With Genotype 2 Or 3 for 14 Weeks: A Pilot StudyHepatology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001